Table 2.
Juvenile Hepatocellular Carcinoma without Hepatitis Infection: Summary of Case Reports.
| No. | Age (years) | Sex | HBsAg/ Ab |
HBcAb | HBV-DNA | HCV-Ab | Family history |
Past history | Drinking/ smoking |
|
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 22) | 25 | F | -/- | - | - | - | - | Mycoplasma pneumonia |
-/- |
| 2 | 23) | 23 | F | -/- | - | - | - | Chronic hepatitis |
Congenital cataract |
-/- |
| 3 | 8) | 17 | M | -/- | - | - | - | - | Bone fracture |
-/- |
| 4 | 24) | 28 | M | -/- | ND | - | - | - | - | -/+ |
| 5 | 25) | 20 | M | -/- | - | - | - | - | - | ND/ND |
| 6 | 26) | 20 | M | -/- | - | - | - | - | Precocious puberty |
ND/ND |
| 7 | 27) | 25 | F | -/- | - | ND | - | ND | Epilepsy | ND/ND |
| 8 | 28) | 25 | F | -/- | - | - | - | - | Ovarian cyst | -/- |
| 9 | 29) | 26 | F | -/- | - | ND | ND | ND | ND | ND |
| 10 | 30) | 39 | F | -/- | - | - | - | ND | ND | -/- |
| 11 | 31) | 41 | M | -/- | - | - | - | - | - | -/- |
| 12 | 32) | 31 | F | -/- | - | - | - | ND | Pyogenic spondylitis |
ND |
| 13 | 33) | 31 | M | -/- | - | - | - | - | Appendicitis | +/- |
| 14 | 34) | 40 | F | -/- | ND | - | - | - | - | -/ND |
| 15 | 35) | 26 | M | -/- | - | - | - | - | - | +/+ |
| 16 | 36) | 30 | M | -/- | - | - | - | - | Asthma | -/ND |
| 17 | 37) | 20’s | M | -/- | - | - | - | - | - | -/- |
| 18 | Onishi et al. | 23 | F | -/- | - | - | - | - | - | -/- |
| No. |
Transfusion
recording |
Drug | AFP | PIVKAII | Treatment | Recurrence |
Outcome
(after treatment) |
|||
| 1 | 22) | - | ND | 35,200 | 14.4 | TAE | No recurrence | Alive 11 months |
||
| 2 | 23) | - | - | 10,320 | Normal | TAE | Brain metastasis (2 years) |
Died 2 years |
||
| 3 | 8) | + | - | <3.0 | <1.0 | TAE, Ope | No recurrence | Alive 19 months |
||
| 4 | 24) | - | - | 37,000 | 18,100 | ND | No recurrence | Died 16 days |
||
| 5 | 25) | - | - | 181.8 | 75,000 | Ope, TAE, PEIT |
Intrahepatic (7 months) |
Alive 36 months |
||
| 6 | 26) | ND | ND | 25,100 | 292 | Ope | No recurrence | Alive 30 months |
||
| 7 | 27) | ND | Phenytoin | 5,011 | 6,022 | TAE, Ope | No recurrence | Alive 21 months |
||
| 8 | 28) | - | - | 1.2 | 329 | Ope | No recurrence | Alive 108 months |
||
| 9 | 29) | ND | ND | >300 | ND | Palliative chemo |
No recurrence | Died 3 months |
||
| 10 | 30) | - | - | Normal | Normal | Ope | ND | ND | ||
| 11 | 31) | - | - | ND | ND | BSC | ND | Died 3 months |
||
| 12 | 32) | ND | - | 4.1 | 39 | Ope | No recurrence | Alive 31 months |
||
| 13 | 33) | - | - | 4.8 | 41 | Ope | ND | Alive 24 months |
||
| 14 | 34) | + | ND | ND | ND | BSC | ND | Died 8 days |
||
| 15 | 35) | - | - | Normal | Normal | Ope | ND | ND | ||
| 16 | 36) | - | - | 2.3 | 24 | Ope | - | Alive 10 months |
||
| 17 | 37) | ND | - | 76,860 | 74,849 | Chemotherapy | ND | Died 9 months |
||
| 18 | Onishi et al. | - | - | 941.8 | 1,170 | Ope | - | Alive 60 months |
||
M: male, F: female, ND: not described, TAE: transcatheter arterial embolization, Ope: operation, PEIT: percutaneous ethanol injection therapy, BSC: best supportive care